Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Eur Acad Dermatol Venereol ; 30(9): 1497-502, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27345620

RESUMO

BACKGROUND: Cutaneous T-cell lymphomas (CTCL) are skin malignancies including mycosis fungoides (MF) and CD30(+) lymphoproliferative disorders (LPD). In early disease, CTCL can be difficult to diagnose, especially in MF for which there is no reliable diagnostic marker. MF/CTCL have increased expression of thymocyte selection-associated HMG box protein (TOX). Although TOX has been proposed to be a diagnostic marker for MF, further validation studies are needed. Moreover, it is unclear what drives TOX expression or its role in MF/CTCL. OBJECTIVE: We hypothesize evaluation of TOX levels across a spectrum of CTCL, including MF precursor (large plaque parapsoriasis, LPP), will help elucidate the implications of altered TOX expression. MATERIALS AND METHODS: TOX staining was performed in MF, CD30(+) LPD, LPP as well as benign inflammatory dermatoses (BID) and normal skin (NS). CTCL cell lines were utilized to evaluate the regulation of TOX. RESULTS: Positive TOX expression was identified in 73.6% of MF cases and in 31.6% of BID/NS. TOX had a positive predictive value (PPV) for MF of 86.7% and a negative predictive value (NPV) of 48.1%. TOX expression in MF was detected more commonly in Black patients (P = 0.015) and less commonly in transformed MF (P = 0.045). LPP had positive TOX staining in 70.0%. In CTCL cells, GATA3 knockdown decreased TOX mRNA and protein expression. TOX expression also decreased in the presence of CTCL therapeutics. CONCLUSION: Our data indicate that TOX is useful as a diagnostic marker in MF. Moreover, TOX expression was evident in LPP, indicating it may have a previously unappreciated role in the development of MF. Finally, our data suggest that GATA3 regulates TOX, revealing insight into TOX regulation.


Assuntos
Proteínas de Grupo de Alta Mobilidade/metabolismo , Linfoma Cutâneo de Células T/metabolismo , Fator de Transcrição GATA3/genética , Proteínas de Grupo de Alta Mobilidade/genética , Humanos , Linfoma Cutâneo de Células T/complicações , Linfoma Cutâneo de Células T/patologia , Micose Fungoide/complicações , RNA Mensageiro/genética
2.
J Eur Acad Dermatol Venereol ; 28(11): 1431-5, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24171863

RESUMO

BACKGROUND: Mycosis fungoides (MF) is a rare, but potentially devastating malignancy. It classically presents with cutaneous patches and plaques and can progress to tumours on the skin with lymph node, blood and visceral involvement. While most patients with MF have a relatively benign disease course, a subset of patients will develop progressive disease that is often fatal. OBJECTIVE: The aim of this study was to identify genetic markers in early MF limited to the skin (stages IA-IIA) that distinguish those patients who will have progressive disease from those who will not, so that early appropriate treatment may be instituted. METHODS: The study includes 18 patients who were diagnosed with early stage MF at the time of biopsy and had follow-up to determine which patients developed progressive disease. RNA was extracted from skin biopsy specimens and analysed for expression of CD3, FOXP3, IFNγ, Interleukin (IL)-4, IL-13, KIR3DL2, MICB, PLS3 and STAT4 by quantitative real-time polymerase chain reaction. RESULTS/CONCLUSIONS: Reduced expression of FOXP3 and STAT4 and increased expression of IL-4 relative to CD3 expression levels were significantly associated with MF progression. Further studies will be needed to fully assess the usefulness of these genetic markers to predict disease progression and guide treatment options in patients diagnosed with early MF.


Assuntos
Biomarcadores Tumorais/metabolismo , Complexo CD3/metabolismo , Fatores de Transcrição Forkhead/metabolismo , Interleucina-4/metabolismo , Micose Fungoide/metabolismo , Fator de Transcrição STAT4/metabolismo , Neoplasias Cutâneas/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais/genética , Biópsia , Complexo CD3/genética , Progressão da Doença , Regulação para Baixo , Feminino , Fatores de Transcrição Forkhead/genética , Humanos , Interleucina-4/genética , Masculino , Pessoa de Meia-Idade , Micose Fungoide/genética , Micose Fungoide/patologia , RNA Mensageiro/metabolismo , Estudos Retrospectivos , Fator de Transcrição STAT4/genética , Pele/metabolismo , Pele/patologia , Neoplasias Cutâneas/genética , Neoplasias Cutâneas/patologia , Regulação para Cima
4.
Br J Dermatol ; 160(1): 183-5, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19016695

RESUMO

BACKGROUND: Staphylococcal colonization of the skin is commonly observed in subjects with atopic dermatitis (AD) and correlates with disease severity. Little is known about whether the degree of T-helper 2 (Th2) polarity in these subjects can also affect the frequency of bacterial colonization in this disease. OBJECTIVES: To determine if there is a correlation between markers of Th2 polarity [serum total IgE, eosinophilia and presence of another atopic disease (allergic rhinitis)] and skin colonization with Staphylococcus aureus in subjects with AD. METHODS: A retrospective chart review was performed of an academic dermatology clinic focused on the treatment of AD with a single provider. RESULTS: Staphylococcus aureus colonization was more commonly observed in subjects with AD who had peripheral eosinophilia, elevated serum IgE levels, and/or a history of or active allergic rhinitis. CONCLUSIONS: Results suggest that Th2 polarity may enhance subjects' risk for bacterial colonization.


Assuntos
Dermatite Atópica/imunologia , Pele/microbiologia , Infecções Cutâneas Estafilocócicas/imunologia , Células Th2/imunologia , Adulto , Biomarcadores/sangue , Polaridade Celular , Dermatite Atópica/microbiologia , Eosinofilia/imunologia , Feminino , Humanos , Imunoglobulina E/sangue , Masculino , Estudos Retrospectivos , Índice de Gravidade de Doença , Infecções Cutâneas Estafilocócicas/microbiologia , Staphylococcus aureus/isolamento & purificação
5.
Lupus ; 18(11): 1015-8, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19762405

RESUMO

Gigantomastia is a rare breast condition characterised by diffuse, rapid, and excessive breast hypertrophy that can result in symptoms ranging from pain to necrosis and sepsis. It typically occurs in the setting of marked hormonal changes such as puberty and pregnancy. Rarely, gigantomastia has been reported to develop in the setting of an autoimmune illness. We present a case of gigantomastia developing in a patient with systemic lupus erythematosus, who was treated with methotrexate and bilateral mammoplasty.


Assuntos
Autoimunidade/imunologia , Mama/patologia , Hipertrofia , Lúpus Eritematoso Sistêmico , Adulto , Antirreumáticos/uso terapêutico , Mama/cirurgia , Feminino , Humanos , Hipertrofia/etiologia , Hipertrofia/patologia , Hipertrofia/terapia , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/patologia , Mamoplastia , Metotrexato/uso terapêutico , Gravidez
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa